Although international medicines regulators adopt a common system to assess the safety and efficacy of new drugs, pre-market evaluation is recognized as incomplete given the much larger post-market experience to follow. Adverse drug reactions contribute to more than 100,000 deaths in the United...

Objectives This paper investigates the pricing strategy (perfect flat pricing, perfect monotonic pricing, intermediate) used for multiple dosage medications listed in the Ontario Drug Benefit Formulary.Methods All multiple dosage solid medications containing a single active ingredient newly...

Spending on direct-to-consumer advertising (DTCA) in the US rapidly increased from $US150 million in 1992 to $US1.2 billion in 1998 (to the end of November). Despite this level of expenditure, there is no literature on how DTCA affects patients' level of knowledge about medications, physician...

Canadian drug laws and regulations have been made increasingly more stringent over the past 40 years and are now considered among the strictest in the world. However, there are still major gaps in the Canadian regulatory process. These deficiencies exist primarily in the areas of the evaluation...

This study was undertaken to compare decisions about medicines innovation made by two Canadian organizations, the Therapeutic Products Directorate (TPD) and the Human Drug Advisory Panel (HDAP), with those made by similar organizations in other countries.

This paper offers an expository discussion of an approach to qualitative health research we call immanent critique. The central analytic move of immanent critique, as we have practiced it, is to explore how claims that are internal to authoritative discourse are experienced by those who have...